#ILC2

Seth Thomas Scanlon

@immunoeditor.bsky.social

1 day ago

So far in March, we've featured papers on:

• how inflammatory #ILC2 migrate
• engineering #CAR-TCells to restore #checkpoint sensitivity
• capturing the earliest events of #TCell #development
• how certain dietary antigens recognized by #Tregs help mediate #OralTolerance

New content every week!

The Lajoie Lab

@lajoielab.bsky.social

3 months ago

Who controls type-2 immunity?

Turns out fibroblasts do , via a C3–IL-33–ILC2 axis that shapes allergic inflammation in vivo. @atakkatan.bsky.social

Our new work highlighted by @cellreports.bsky.social

#Immunology #StromalBiology #Allergy #Asthma #ILC2 #IL33 #Complement

@atakkatan.bsky.social

3 months ago

Thrilled to share our work that has indeed *complemented* ongoing research in the lab!!!🙌
#complement #IL33 #fibroblast #ILC2 #airwayallergy

Naina Gour

@nainagour.bsky.social

3 months ago

Our cool new paper depicting fibroblasts more than a scaffold during airway allergy. #Il33 #ILC2 #complement

Seth Thomas Scanlon

@immunoeditor.bsky.social

5 months ago

Group 2 innate lymphoid cells regulate nociceptive and gait functions of the peripheral nervous system ILC2-neuron cross-talk contributes to the maintenance of nerve structure and function of the peripheral nervous system.

Now in #Science #Immunology: Deshpande, Klose, & al at Charité—Universitätsmedizin Berlin report that #ILC2 resident in #PNS communicate with neurons via #IL13 to maintain #nerve structure & pain thresholds. Mice lacking ILC2 or whose neurons are Il4ra-KO exhibit #hypersensitivity & #gait defects!

Sarah Crome

@sarahcrome.bsky.social

6 months ago

This meeting has always been a highlight for the ILC community, and Vancouver 2026 already features an exciting lineup of confirmed speakers.

🔗 ilc6vancouver.com

#ILC6 #Immunology #InnateLymphoidCells, #ILC, #ILC2, #ILC3, #NKcells, #ILC1 #Immunosky

Sarah Crome

@sarahcrome.bsky.social

9 months ago

Excited this work is out! #ILCs, #immunology, #immunosky, #ILC2, #celltherapy. Full post to come, but for now thank you to our amazing collaborators and the generous patients and families that made this work possible. @uhn.ca @uoft.bsky.social @bbdc-uoft.bsky.social

Seth Thomas Scanlon

@immunoeditor.bsky.social

9 months ago

ILC3s promote intestinal tuft cell hyperplasia and anthelmintic immunity through RANK signaling Gut ILC3s help type 2 immunity by boosting tuft cell differentiation.

In the latest #Science #Immunology: researchers @ Tsinghua U report that #ILC3 augment group #ILC2 #anthelmintic immune responses in 🐁! Upon N. braziliensis infection, ILC3-derived #RANKL synergizes w/ #IL13 to facilitate intestinal #TuftCell expansion, which amplifies ILC2 responses!

MSK Library

@msklibrary.bsky.social

1 year ago

Featured today by @MSKLibrary: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer

#IL33 #ILC2 #TertiaryLymphoidStructures #PancreaticCancer #CancerImmunology

www.nature.com/articles/s41...

Jovita Mezquita Pla

@jovitamezquitapla.bsky.social

1 year ago

El enigma i la grandessa de les cèl·lules #ILC2. Nous paradigmes.

Les cèl·lules del sistema #immunitari (SI) també ens defensen de morir de gana.

Treballant en equip esdevenen funcionals i indestructibles.

Hiroshi Yano, PhD

@hirothehero.bsky.social

1 year ago

IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer - Nature IL-33 induces tertiary lymphoid structures.

#ILC2 as an inducer of tertiary lymphoid structures (#TLS) in cancer!

Beautiful study by Balachandran group at MSK.

I'm so happy to have been able to contribute to this exciting story!

www.nature.com/articles/s41...

x.com/thevinodlab/...

Sarah Crome

@sarahcrome.bsky.social

1 year ago

#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2 #Research #Immunosky

Sarah Crome

@sarahcrome.bsky.social

1 year ago

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses Reid et al. report that IL-10⁺ ILC2 cell therapy inhibits graft-versus-host disease (GVHD) in humanized mice, consistent with patient studies where IL-10⁺ ILC2s are associated with protection from GVHD. Human IL-10⁺ ILC2s express CD49d and CD86 and inhibit allogeneic T cell responses via an IL-4- and IL-10-dependent mechanism. These findings support harnessing IL-10⁺ ILC2s therapeutically.

🎉 New Year, New Paper! We're excited to share our latest study led by @kyletreid.bsky.social, demonstrating human IL-10-producing ILC2s can be harnessed in cell therapies. 🧬✨ www.cell.com/cell-reports...
#Immunology #Transplantation #GVHD #RegenerativeMedicine #CellTherapy #ILC2